Mehmet Ali Astarcioglu

Mehmet Ali Astarcioglu

Auto-generated profile, based on publicly available information

Mehmet Ali Astarcioglu

Kutahya Health Sciences University, Faculty of Medicine, Department of Cardiology, Kutahya, Türkiye

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MÖMehmet Taha Özkan
Mehmet Taha Özkan
SGSabahattin Gündüz
Sabahattin Gündüz
MBMurat Biteker
Murat Biteker
MAMehmet Ali Astarcioglu
Mehmet Ali Astarcioglu
CÇCihan Çevik
Cihan Çevik
NÖNihal Özdemir
Nihal Özdemir

1 August 2015 in American Heart Journal
Verified
Journal Article
Closed access
MÖMehmet Özkan
Mehmet Özkan
SGSabahattin Gündüz
Sabahattin Gündüz
OGOzan Mustafa Gürsoy
Ozan Mustafa Gürsoy
SKSüleyman Karakoyun
Süleyman Karakoyun
MAMehmet Ali Astarcıoğlu
Mehmet Ali Astarcıoğlu
AEAli Metin Esen
Ali Metin Esen

30 July 2013 in Circulation
Verified
Journal Article
Closed access
MÖMehmet Taha Özkan
Mehmet Taha Özkan
BÇBeytullah Çakal
Beytullah Çakal
SKSüleyman Karakoyun
Süleyman Karakoyun
OGOzan Mustafa Gürsoy
Ozan Mustafa Gürsoy
CÇCihan Çevik
Cihan Çevik
MYMustafa Yıldız
Mustafa Yıldız
Background—: Prosthetic valve thrombosis during pregnancy is life-threatening for mother and fetus, and the treatment of this complication is unclear. Cardiac surgery in pregnancy is associated with very high maternal and fetal mortality and morbidity. Thrombolytic therapy has rarely been used in these patients. The aim of this study is to evaluate the safety and efficacy of low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator for the treatment of prosthetic valve thrombosis in pregnant women. Methods and Results—: Between 2004 and 2012, tissue-type plasminogen activator was administered to 24 consecutive women in 25 pregnancies with 28 prosthetic valve thrombosis episodes (obstructive, n=15; nonobstructive, n=13). Mean age of the patients was 29±6 years. Thrombolytic therapy sessions were performed under transesophageal echocardiography guidance. The mean dose of tissue-type plasminogen activator used was 48.7±29.5 mg (range, 25–100mg). All episodes resulted in complete thrombus lysis after thrombolytic therapy. One patient had placental hemorrhage with preterm live birth at the 30th week, and 1 patient had minor bleeding. Conclusions—: Low-dose, slow infusion of tissue-type plasminogen activator with repeated doses as needed is an effective therapy with an excellent thrombolytic success rate for the treatment of prosthetic valve thrombosis in pregnant women. This protocol also seems to be safer than cardiac surgery or any alternative medical strategies published to date. Thrombolytic therapy should be considered first-line therapy in pregnant patients with prosthetic valve thrombosis.

1 December 2015 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
SGSabahattin Gündüz
Sabahattin Gündüz
MÖMehmet Özkan
Mehmet Özkan
MKMacit Kalçik
Macit Kalçik
OGOzan Mustafa Gürsoy
Ozan Mustafa Gürsoy
MAMehmet Ali Astarcioğlu
Mehmet Ali Astarcioğlu
TGTahsin Güneysu
Tahsin Güneysu
Background—: Distinguishing pannus and thrombus in patients with prosthetic valve dysfunction is essential for the selection of proper treatment. We have investigated the utility of 64-slice multidetector computed tomography (MDCT) in distinguishing between pannus and thrombus, the latter amenable to thrombolysis. Methods and Results—: Sixty-two (23 men, mean age 44±14 years) patients with suspected mechanical prosthetic valve dysfunction assessed by transesophageal echocardiography were included in this prospective observational trial. Subsequently, MDCT was performed before any treatment was started. Periprosthetic masses were detected by MDCT in 46 patients, and their attenuation values were measured as Hounsfield Units (HU). Patients underwent thrombolysis unless contraindicated, and those with a contraindication or failed thrombolysis underwent surgery. A mass which was completely lysed or surgically detected as a clot was classified as thrombus, whereas a mass which was surgically detected as tissue overgrowth was classified as pannus. A definitive diagnosis could be achieved in 37 patients with 39 MDCT masses (22 thrombus and 17 pannus). The mean attenuation value of 22 thrombotic masses was significantly lower than that in 17 pannus (87±59 versus 322±122; P <0.001). Area under the receiver operating characteristic curve was 0.96 (95% confidence interval: 0.91–0.99; P <0.001), and a cutoff point of HU≥145 provided high sensitivity (87.5%) and specificity (95.5%) in discriminating pannus from thrombus. Complete lysis was more common for masses with HU90) is associated with reduced lysis rates.

1 October 2015 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MAMehmet Ali Astarcioglu
Mehmet Ali Astarcioglu
TSTaner Sen
Taner Sen
CKCelal Kilit
Celal Kilit
HDHalil Ibrahim Durmus
Halil Ibrahim Durmus
GGGokhan Gozubuyuk
Gokhan Gozubuyuk
BABasri Amasyali
Basri Amasyali

1 October 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MÖMehmet Özkan
Mehmet Özkan
OGOzan Mustafa Gürsoy
Ozan Mustafa Gürsoy
MAMehmet Ali Astarcıoğlu
Mehmet Ali Astarcıoğlu
SGSabahattin Gündüz
Sabahattin Gündüz
BÇBeytullah Çakal
Beytullah Çakal
CCCihan Cevik
Cihan Cevik